New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
08:13 EDTTKMRTekmira Pharmaceuticals to expand, advance pipeline of proprietary products
Tekmira Pharmaceuticals announced its key product development, corporate, and partner milestones for 2013. "Tekmira has been at the forefront of the RNAi technology revolution over the last decade, and 2012 proved to be a pivotal year for the RNAi field where Tekmira's LNP technology enabled multiple promising sets of human clinical data. It is Tekmira's deep knowledge and our ability to continuously innovate and improve our LNP technology platform which is driving the RNAi field forward," said Dr. Mark J. Murray, Tekmira's president and CEO. "Building upon this positive momentum, in the year ahead, we will expand and advance Tekmira's pipeline of proprietary products, in order to maximize value for our shareholders. We intend to present results from our Phase I clinical trial with TKM-PLK1, our lead cancer program, and we anticipate it will enter Phase II clinical trials later this year. We will continue to advance our TKM-Ebola product in collaboration with the U.S. Department of Defense's TMT program. And, we expect to nominate and move forward with our next target for development. Looking at our partners, we anticipate results from Alnylam's ALN-TTR02 Phase II trial in mid-2013 and the initiation of a Phase III trial by the end of 2013 and we expect to receive $10M in milestone payments from Alnylam in 2013. In addition, we are entitled to future royalty payments based on sales of Marqibo, which was recently approved by the FDA. With clarity around the intellectual property protecting our LNP technology platform, we are well-positioned to pursue product, platform and strategic partnering deals," added Dr. Murray.
News For TKMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
18:51 EDTTKMRTekmira surges after hours on first confirmed U.S. Ebola case
Subscribe for More Information
18:36 EDTTKMROn The Fly: After Hours Movers
Subscribe for More Information
17:58 EDTTKMRCDC confirms first U.S. patient diagnosed with Ebola virus
Subscribe for More Information
17:39 EDTTKMRCompanies developing Ebola treatments rise after CDC confirms U.S. Ebola case
Subscribe for More Information
16:44 EDTTKMRTekmira up 12% after hours following CDC confirmation of Ebola case in U.S.
September 26, 2014
07:47 EDTTKMREMA to review BioCryst, Sarepta, Tekmira experimental Ebola medicines
Subscribe for More Information
September 25, 2014
06:41 EDTTKMRTekmira volatility flat on wide price movement
Subscribe for More Information
September 23, 2014
06:13 EDTTKMRTekmira to collaborate with international consortium researching Ebola
Subscribe for More Information
September 22, 2014
13:02 EDTTKMRTekmira surges on FDA authorization of TKM-Ebola for emergency use
Subscribe for More Information
12:57 EDTTKMRTekmira up 20% following FDA authorization of TKM-Ebola for emergency use
09:16 EDTTKMRTekmira establishes regulatory framework for emergency use of TKM-Ebola
Subscribe for More Information
September 17, 2014
15:02 EDTTKMRCongressman questions why FDA hasn't moved on Ebola drug, The Hill says
Republican Congressman Michael Burgess said he was "bewildered" as to why the FDA continues to have a hold on Tekmira's TKS-Ebloa drug, a treatment for Ebola, according to The Hill. However, Democratic Congresswoman Betty McCollum warned against using Africa as a "testing ground" for drugs that haven't been property screened, the website noted. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use